HLB Pharmaceutical Price To Sales vs. Net Income

047920 Stock  KRW 23,400  700.00  2.90%   
Taking into consideration HLB Pharmaceutical's profitability measurements, HLB Pharmaceutical Co may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess HLB Pharmaceutical's ability to earn profits and add value for shareholders.
For HLB Pharmaceutical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of HLB Pharmaceutical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well HLB Pharmaceutical Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between HLB Pharmaceutical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of HLB Pharmaceutical Co over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between HLB Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if HLB Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HLB Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

HLB Pharmaceutical Net Income vs. Price To Sales Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining HLB Pharmaceutical's current stock value. Our valuation model uses many indicators to compare HLB Pharmaceutical value to that of its competitors to determine the firm's financial worth.
HLB Pharmaceutical Co is number one stock in price to sales category among its peers. It also is number one stock in net income category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value HLB Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for HLB Pharmaceutical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

HLB Net Income vs. Price To Sales

Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

HLB Pharmaceutical

P/S

 = 

MV Per Share

Revenue Per Share

 = 
5.60 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

HLB Pharmaceutical

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(13.23 B)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.

HLB Net Income Comparison

HLB Pharmaceutical is currently under evaluation in net income category among its peers.

HLB Pharmaceutical Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in HLB Pharmaceutical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, HLB Pharmaceutical will eventually generate negative long term returns. The profitability progress is the general direction of HLB Pharmaceutical's change in net profit over the period of time. It can combine multiple indicators of HLB Pharmaceutical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
HLB Pharmaceutical Co., Ltd, a pharmaceutical company, develops peptide drugs in South Korea. HLB Pharmaceutical Co., Ltd was founded in 1998 and is headquartered in Namyangju, South Korea. HLBPHARMA is traded on Korean Securities Dealers Automated Quotations in South Korea.

HLB Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on HLB Pharmaceutical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of HLB Pharmaceutical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the HLB Pharmaceutical's important profitability drivers and their relationship over time.

Use HLB Pharmaceutical in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLB Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLB Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

HLB Pharmaceutical Pair Trading

HLB Pharmaceutical Co Pair Trading Analysis

The ability to find closely correlated positions to HLB Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLB Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLB Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLB Pharmaceutical Co to buy it.
The correlation of HLB Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLB Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLB Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HLB Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your HLB Pharmaceutical position

In addition to having HLB Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Wholesale Thematic Idea Now

Wholesale
Wholesale Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Wholesale theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Wholesale Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in HLB Stock

To fully project HLB Pharmaceutical's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of HLB Pharmaceutical at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include HLB Pharmaceutical's income statement, its balance sheet, and the statement of cash flows.
Potential HLB Pharmaceutical investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although HLB Pharmaceutical investors may work on each financial statement separately, they are all related. The changes in HLB Pharmaceutical's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on HLB Pharmaceutical's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.